Mesoblast Limited

Mesoblast reported FY2026 net revenue of $115 million, including fourth-quarter net revenue of $36 million. Gross profit on total sales, excluding amortization expenses, was $110 million. Product development costs were $17.3 million, continued R&D investment in Phase 3 programs was roughly $21.2 million, and sales and marketing expense increased by about $18 million. Net loss after taxes improved 44% to $57.5 million. The company ended the year with $103 million of cash, had net cash usage of $43.8 million, and second-half cash burn was $13.4 million versus $50 million in the prior-year period. For guidance, management said it expects double-digit growth in the coming 12-month period for RYONCIL and expects fiscal 2027 cash burn to be less than fiscal 2026, but declined to give a specific quarter for cash flow positivity.

Silviu Itescu framed FY2026 as the company’s transition from an R&D business to a commercial one, emphasizing that RYONCIL is now the only FDA-approved mesenchymal stromal cell product and that its revenues are being reinvested into Phase 3 programs and manufacturing. He repeatedly pointed to what he called Mesoblast’s “moat,” including more than 1,100 patents and patent applications, FDA alignment, and scale-up/manufacturing know-how. His tone was constructive and expansion-oriented, with focus on pediatric and adult GvHD, Duchenne muscular dystrophy, chronic low back pain, and inflammatory heart failure.

James O’Brien focused on the financial leverage coming from commercial revenue and tighter spend. He cited $115 million of net revenue, $17.3 million of product development costs, $21.2 million of Phase 3 R&D investment, and about $18 million of additional sales and marketing spend to support RYONCIL. He said net loss after tax declined 44% to $57.5 million, cash was $103 million at year-end, net cash usage was $43.8 million, and second-half cash burn improved to $13.4 million from $50 million a year earlier. He also noted the $125 million credit facility at 8% interest with no principal amortization for five years, and said fiscal 2027 cash burn should be lower than fiscal 2026.

Analysts focused on how quickly RYONCIL could grow, especially in the pediatric GvHD business, and what would drive a broader launch in Duchenne muscular dystrophy. Management said it expects double-digit growth in the next 12 months, but did not give precise revenue guidance, and explained Duchenne was selected because earlier treatment in younger children may better address inflammation than later-stage approaches. Questions also centered on the adult GvHD study; management said the 180-patient trial is powered around 85% to 90%, interim analysis is expected when about 57% of patients are enrolled, and both the full study and interim route have been vetted with the FDA for an sBLA filing. On financing, management said it would keep options open but believes current cash and long-term debt structure are sufficient to support planned programs.